Fiduciary Group LLC Has $9.62 Million Stake in Amgen Inc. (NASDAQ:AMGN)

Fiduciary Group LLC lowered its stake in Amgen Inc. (NASDAQ:AMGN) by 7.8% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 33,381 shares of the medical research company’s stock after selling 2,828 shares during the quarter. Amgen makes up approximately 1.1% of Fiduciary Group LLC’s investment portfolio, making the stock its 23rd largest position. Fiduciary Group LLC’s holdings in Amgen were worth $9,615,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently made changes to their positions in AMGN. OFI Invest Asset Management bought a new position in shares of Amgen in the third quarter worth about $26,000. Briaud Financial Planning Inc bought a new position in shares of Amgen in the third quarter worth about $26,000. BOK Financial Private Wealth Inc. bought a new position in shares of Amgen in the fourth quarter worth about $29,000. Providence Capital Advisors LLC bought a new position in shares of Amgen in the third quarter worth about $30,000. Finally, Planned Solutions Inc. bought a new position in shares of Amgen in the fourth quarter worth about $30,000. Institutional investors own 76.50% of the company’s stock.

Amgen Stock Up 0.2 %

NASDAQ AMGN traded up $0.60 during mid-day trading on Friday, hitting $269.98. The company’s stock had a trading volume of 2,436,959 shares, compared to its average volume of 2,035,139. The company’s 50 day simple moving average is $275.10 and its 200 day simple moving average is $281.52. Amgen Inc. has a twelve month low of $211.71 and a twelve month high of $329.72. The company has a current ratio of 1.65, a quick ratio of 1.13 and a debt-to-equity ratio of 10.14. The firm has a market capitalization of $144.81 billion, a price-to-earnings ratio of 21.62, a PEG ratio of 2.61 and a beta of 0.58.

Amgen (NASDAQ:AMGN) last posted its quarterly earnings results on Tuesday, February 6th. The medical research company reported $4.71 earnings per share (EPS) for the quarter, beating the consensus estimate of $4.66 by $0.05. Amgen had a net margin of 23.83% and a return on equity of 154.27%. The business had revenue of $8.20 billion during the quarter, compared to the consensus estimate of $8.13 billion. During the same quarter last year, the firm posted $4.09 EPS. Amgen’s revenue was up 19.8% compared to the same quarter last year. Analysts anticipate that Amgen Inc. will post 19.43 earnings per share for the current year.

Amgen Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, June 7th. Shareholders of record on Friday, May 17th will be issued a dividend of $2.25 per share. This represents a $9.00 dividend on an annualized basis and a yield of 3.33%. The ex-dividend date is Thursday, May 16th. Amgen’s dividend payout ratio is 72.06%.

Analyst Ratings Changes

A number of brokerages recently issued reports on AMGN. Oppenheimer reiterated an “outperform” rating and issued a $350.00 price objective on shares of Amgen in a report on Thursday, February 1st. Truist Financial restated a “buy” rating and set a $320.00 price target on shares of Amgen in a report on Friday, April 12th. Royal Bank of Canada restated an “outperform” rating and set a $329.00 price target on shares of Amgen in a report on Wednesday, April 3rd. The Goldman Sachs Group raised their price target on shares of Amgen from $313.00 to $350.00 and gave the stock a “buy” rating in a report on Wednesday, February 7th. Finally, SVB Leerink lowered shares of Amgen from an “outperform” rating to a “market perform” rating and lowered their price target for the stock from $324.00 to $318.00 in a report on Wednesday, February 7th. Ten research analysts have rated the stock with a hold rating and ten have issued a buy rating to the stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $296.95.

Amgen Company Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.